Acute Lung Injury – Pipeline Review, H1 2012

Introduction

Global Markets Direct’s, 'Acute Lung Injury - Pipeline Review, H1 2012', provides an overview of the Acute Lung Injury therapeutic pipeline. This report provides information on the therapeutic development for Acute Lung Injury, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Acute Lung Injury. 'Acute Lung Injury - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Acute Lung Injury.
- A review of the Acute Lung Injury products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Acute Lung Injury pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Highlights

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Acute Lung Injury.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Acute Lung Injury pipeline depth and focus of Acute Lung Injury therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
[Studien Infos ausblenden]

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Acute Lung Injury Overview 7
Therapeutics Development 8
An Overview of Pipeline Products for Acute Lung Injury 8
Acute Lung Injury Therapeutics under Development by Companies 10
Acute Lung Injury Therapeutics under Investigation by Universities/Institutes 12
Late Stage Products 13
Comparative Analysis 13
Mid Clinical Stage Products 14
Comparative Analysis 14
Early Clinical Stage Products 15
Comparative Analysis 15
Discovery and Pre-Clinical Stage Products 16
Comparative Analysis 16
Acute Lung Injury Therapeutics – Products under Development by Companies 17
Acute Lung Injury Therapeutics – Products under Investigation by Universities/Institutes 18
Companies Involved in Acute Lung Injury Therapeutics Development 19
GlaxoSmithKline plc 19
Quark Pharmaceuticals, Inc. 20
Discovery Laboratories, Inc. 21
Silence Therapeutics plc. 22
Advanced Life Sciences Holdings, Inc. 23
REVOTAR Biopharmaceuticals AG 24
Altor BioScience Corporation 25
NovImmune SA 26
KYORIN Pharmaceutical Co., Ltd. 27
Faron Pharmaceuticals, Ltd. 28
Acute Lung Injury – Therapeutics Assessment 29
Assessment by Monotherapy Products 29
Assessment by Combination Products 30
Assessment by Route of Administration 31
Assessment by Molecule Type 33
Drug Profiles 36
ALS-886 - Drug Profile 36
NI-0101 - Drug Profile 37
SB681323 - Drug Profile 38
Aerosurf - Drug Profile 40
ALT-836 - Drug Profile 42
Respiratory And Inflammatory Diseases Program - Drug Profile 44
Bimosiamose - Drug Profile 45
KRP-109 - Drug Profile 47
APN01 - Drug Profile 48
N-Acetyl Cysteine - Drug Profile 50
Calfactant - Drug Profile 51
Calfactant - Drug Profile 52
Human albumin - Drug Profile 53
Hetastarch - Drug Profile 54
Atu111 - Drug Profile 55
FP-1201 - Drug Profile 56
GM-CSF - Drug Profile 58
N-acetylcysteine - Drug Profile 59
Rosuvastatin - Drug Profile 60
Methylprednisolone - Drug Profile 61
Furosemide + Albumin + Norepinephrine + Vasopressin + Phenylephrine + Epinephrine + Dobutamine - Drug Profile 62
Acute Lung Injury Therapeutics – Drug Profile Updates 64
Acute Lung Injury Therapeutics – Discontinued Products 68
Acute Lung Injury Therapeutics - Dormant Products 69
Acute Lung Injury – Product Development Milestones 70
Featured News & Press Releases 70
Appendix 76
Methodology 76
Expert Panel Validation 77
Contact Us 77
Disclaimer 77
[Inhaltsverzeichnis ausblenden]

List of Tables
Number of Products Under Development for Acute Lung Injury, H1 2012 10
Products under Development for Acute Lung Injury – Comparative Analysis, H1 2012 11
Number of Products under Development by Companies, H1 2012 13
Number of Products under Investigation by Universities/Institutes, H1 2012 14
Comparative Analysis by Late Stage Development, H1 2012 15
Comparative Analysis by Mid Clinical Stage Development, H1 2012 16
Comparative Analysis by Early Clinical Stage Development, H1 2012 17
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2012 18
Products under Development by Companies, H1 2012 19
Products under Investigation by Universities/Institutes, H1 2012 20
GlaxoSmithKline plc, H1 2012 21
Quark Pharmaceuticals, Inc., H1 2012 22
Discovery Laboratories, Inc., H1 2012 23
Silence Therapeutics plc., H1 2012 24
Advanced Life Sciences Holdings, Inc., H1 2012 25
REVOTAR Biopharmaceuticals AG, H1 2012 26
Altor BioScience Corporation, H1 2012 27
NovImmune SA, H1 2012 28
KYORIN Pharmaceutical Co., Ltd., H1 2012 29
Faron Pharmaceuticals, Ltd., H1 2012 30
Assessment by Monotherapy Products, H1 2012 31
Assessment by Combination Products, H1 2012 32
Assessment by Stage and Route of Administration, H1 2012 34
Assessment by Molecule Type, H1 2012 37
Acute Lung Injury Therapeutics – Drug Profile Updates 66
Acute Lung Injury Therapeutics – Discontinued Products 70
Acute Lung Injury Therapeutics – Dormant Products 71
List of Figures
Number of Products under Development for Acute Lung Injury, H1 2012 10
Products under Development for Acute Lung Injury – Comparative Analysis, H1 2012 11
Products under Development by Companies, H1 2012 12
Products under Investigation by Universities/Institutes, H1 2012 14
Late Stage Products, H1 2012 15
Mid Clinical Stage Products, H1 2012 16
Early Clinical Stage Products, H1 2012 17
Discovery and Pre-Clinical Stage Products, H1 2012 18
Assessment by Monotherapy Products, H1 2012 31
Assessment by Combination Products, H1 2012 32
Assessment by Route of Administration, H1 2012 33
Assessment by Stage and Route of Administration, H1 2012 34
Assessment by Molecule Type, H1 2012 35
Assessment by Stage and Molecule Type, H1 2012 36
[Tabellenverzeichnis ausblenden]